GSK and Theravance announce completion of the Phase III programme for once-daily LAMA/LABA in COPD
24 August 2012 | By GlaxoSmithKline
GSK confirms its intention to commence global filings from the end of 2012...
List view / Grid view
24 August 2012 | By GlaxoSmithKline
GSK confirms its intention to commence global filings from the end of 2012...
24 August 2012 | By Boehringer Ingelheim
Indirect comparison based on the RE-LY® trial and the Rocket AF trial suggests advantages of Pradaxa® in stroke prevention in patients with atrial fibrillation...
23 August 2012 | By GlaxoSmithKline
“The start of the Phase III programme in rheumatoid arthritis is an important milestone in our collaboration with Janssen Biologics.”
22 August 2012 | By Daiichi Sankyo
Inavir® Dry Powder Inhaler significantly reduces the incidence of influenza infection...
22 August 2012 | By H. Lundbeck A/S
Lundbeck has appointed Andreas Eggert as senior vice president for global product strategy and Klaus Abel as vice president...
21 August 2012 | By Pfizer
The U.S. FDA has extended the action date by three months for the NDA for tofacitinib...
21 August 2012 | By ANDREW LLOYD & ASSOCIATES
CTO appointment reinforces senior management expertise in biomarker industry...
21 August 2012 | By kdm communications limited
Tecan has launched the QC Kit, a total solution for liquid handling performance verification testing on Freedom EVO® workstations...
21 August 2012 | By Citigate Dewe Rogerson
C3BS announces the appointment of Dr Alexander Milstein...
20 August 2012 | By Abbott
XIENCE Xpedition™ Everolimus Eluting Coronary Stent System receives CE Mark...
17 August 2012 | By HORIBA Scientific
Fully automated extended wavelength range capability and new generation of software offer versatility without compromise...
17 August 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta® (linagliptin) tablets for use as add-on therapy to insulin.
17 August 2012 | By Biogen Idec
New collaboration in support of Science, Technology, Engineering, and Math education...
15 August 2012 | By Phenomenex
Fasha Mahjoor, founder and CEO of Phenomenex, will leap off the 87th floor of The Shard in London on the 3rd of September...
15 August 2012 | By Maitland
Study to test Debio 0932 in patients with advanced non-small cell lung cancer...